WallSt.net Announces Upcoming Interview With CEO Of Immunosyn C...( LA JOLLA Calif. Nov. 14 /- Stephe...)

LA JOLLA, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Stephen D. Ferrone, CEO of Immunosyn Corporation (OTC Bulletin Board: IMYN) will be featured in an exclusive interview with http://www.wallst.net scheduled for November 16 at 8:00 A.M. PST. The interview will be posted on http://www.wallst.net by 5 P.M. EST on November 16, 2007.

The interview will cover topics including Immunosyn's market potential, growth initiatives, competitive edge, recent news and milestones that investors should watch for.

"This interview is a part of our strategic market communication plan which includes meeting with brokers and institutional managers as well as taking part in interviews," says Stephen D. Ferrone, CEO and President of Immunosyn.

To hear the interview in its entirety, visit http://wallst.net and click on "Interviews." The interview can be accessed by locating the company's ticker symbol (IMYN) under the appropriate exchange (OTCBB) at the top of the "Interviews" section or by entering the company's ticker symbol (IMYN) in the Search Archive window.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and
'/>"/>